Fabio Socciarelli

Fabio Socciarelli

Auto-generated profile, based on publicly available information

Fabio Socciarelli

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
EMEugenio Morelli
Eugenio Morelli
CRCaroline Fidalgo Ribeiro
Caroline Fidalgo Ribeiro
SRSilvia D. Rodrigues
Silvia D. Rodrigues
CGClaire Gao
Claire Gao
FSFabio Socciarelli
Fabio Socciarelli
MLMassimo F. Loda
Massimo F. Loda
Purpose: In multiple myeloma, tumor cells reprogram metabolic pathways to sustain growth and monoclonal immunoglobulin production. This study examines acetyl-CoA carboxylase 1 (ACC1), the enzyme driving the rate-limiting step in de novo lipogenesis, in multiple myeloma metabolic reprogramming, particularly in c-MYC (MYC)–driven subtypes. Experimental Design: ACC1 expression was evaluated across multiple myeloma genetic subgroups, focusing on MYC translocations. Functional studies using ACC1 inhibitors and genetic knockdown assessed multiple myeloma cell growth, lipid synthesis, and metabolic homeostasis in vitro and in vivo. The role of MYC overexpression in ACC1 sensitivity was examined, with palmitate rescue experiments. Lipidomic analysis and assessments of endoplasmic reticulum (ER) stress, protein translation, and oxidative damage elucidated underlying mechanisms. Results: ACC1 was overexpressed in MYC-translocated multiple myeloma. Its inhibition or knockdown reduced multiple myeloma cell growth in vitro and in vivo, particularly in MYC-overexpressing cells. ACC1 knockdown suppressed de novo lipid synthesis, partially rescued by palmitate. Lipidomic disruptions increased cholesterol ester desaturation and altered phospholipid ratios, inducing ER stress, impaired translation, protein carbonylation, oxidative damage, and apoptosis. Conclusions: ACC1 is a metabolic vulnerability in MYC-driven multiple myeloma. Inhibiting ACC1 disrupts lipid homeostasis, induces ER stress, and causes oxidative damage, impairing cell survival. Targeting lipid synthesis pathways, especially in MYC-dependent subtypes, offers a promising therapeutic strategy for multiple myeloma.

29 July 2025 in Laboratory Investigation
Verified
Journal Article
Closed access
MOMohamed Omar
Mohamed Omar
Giuseppe Nicolò FanelliGiuseppe Nicolò Fanelli
Giuseppe Nicolò Fanelli
FSFabio Socciarelli
Fabio Socciarelli
VUVarun Ullanat
Varun Ullanat
SPSreekar Reddy Puchala
Sreekar Reddy Puchala
MLMassimo F. Loda
Massimo F. Loda

21 September 2025 in bioRxiv
Verified
Preprint
Open access
AAAli Amiryousefi
Ali Amiryousefi
JWJeremiah Wala
Jeremiah Wala
JLJia-Ren Lin
Jia-Ren Lin
BLBrian William Labadie
Brian William Labadie
AAAishwarya Atmakuri
Aishwarya Atmakuri
PSPeter Sorger
Peter Sorger
The spatial arrangement of immune cells in the tumor microenvironment (TME) varies widely, from dispersed to clustered and tumor excluded to infiltrating. Multiplexed spatial profiling is an effective means of characterizing tumor-infiltrating lymphocytes (TILs) and immune complexes such as tertiary lymphoid structures (TLS) in the TME. However, few approaches have been described for objectively parametrizing patterns of immune organization and assessing their association with biological or clinical variables. This makes it difficult to evaluate whether a set of tumors is relatively immunologically cold or hot. Here we describe an intuitive set of statistical tools (available in the R package, tlsR ) for characterizing lymphocyte patterns in the TME of solid cancers. We apply tlsR to primary prostate cancer (PCa), which is often described as immunologically ‘cold’. Using a cohort of 29 radical prostatectomy specimens stratified into low Gleason-grade (LGG; n=15) and high Gleason-grades (HGG; n =14) we show that HGG PCa is significantly more infiltrated than LGG PCa with lymphocytes organized into B cell or T cell enriched immune clusters (BICs and TICs). A subset of these ICs have the B and T cell zonation and follicular dendritic cells characteristic of a bona fide TLS. HGGs are also enriched with ICs containing precursor exhausted T cells (T pex ) and proliferating B cells and their tumor compartments harbor granzyme-B + cytotoxic T cells in contact with cancer cells. Thus, far from being cold, a subset of HGG PCa has features associated with active immune surveillance, a finding with implications for emerging PCa immunotherapies.

23 June 2026 in Cancer Research
Verified
Journal Article
Open access
NSNabil Siddiqui
Nabil Siddiqui
LZLi Zhang
Li Zhang
GDGabriel DeLeon
Gabriel DeLeon
NNNada Naguib
Nada Naguib
TZTuo Zhang
Tuo Zhang
MBMichelle S. Bradbury
Michelle S. Bradbury
The limited efficacy of immunotherapies in advanced prostate cancer stems from a tumor microenvironment (TME) in which myeloid-driven immune suppression, stromal remodeling, and metabolic barriers converge to limit antitumor immunity. In this study, we characterized the immunometabolic properties of an ultrasmall prostate-specific membrane antigen–targeting silica particle therapy as a first-in-class strategy to reprogram the Toll-like receptor (TLR)–ferroptosis axis in MYC-driven prostate cancer. As single agents, these particles suppressed lipid and steroid biosynthesis, disrupted lipid peroxidation control, and impaired nutrient flux, sensitizing tumors to ferroptosis. Coordinated redox remodeling, stromal reprogramming, and innate immune activation reversed myeloid suppression and promoted CD8+ T-cell infiltration. When combined with CSF-1R inhibition and immune checkpoint blockade, the particles suppressed tumor growth, extended survival beyond 100 days, and achieved up to 50% complete remission in MYC-overexpressing models. These findings position TLR–ferroptosis axis remodeling as a mechanistic blueprint for rational, particle-driven immunotherapies with broad translational potential in prostate cancer and other immunologically refractory malignancies. Significance: Clinically validated, PSMA-targeted ultrasmall core-shell silica particles reprogram immunometabolic pathways via a TLR–ferroptosis axis, enabling tumor microenvironment remodeling and potentiating checkpoint blockade in prostate cancer, with translational implications for treatment-resistant disease.

28 July 2013 in Case Reports in Rheumatology
Verified
Journal Article
Open access
PDF file
MFM. Fantò
M. Fantò
SSS. Salemi
S. Salemi
FSF. Socciarelli
F. Socciarelli
ABArmando Bartolazzi
Armando Bartolazzi
GNG. A. Natale
G. A. Natale
RDR. D'AMelio
R. D'AMelio
A 30-year-old woman affected by Mixed Connective Tissue Disease with scleroderma spectrum developed a facial eruption, a clinical and histological characteristic of subacute cutaneous lupus erythematosus (SCLE). Speckled anti-nuclear antibodies, high-titer anti-ribonucleoprotein1, anti-Sm, anti-Cardiolipin (aCL) IgG/IgM, and anti-Ro/SSA antibodies were positive. SCLE was resistant to Azathioprine, Hydroxychloroquine, and Methotrexate while Mycophenolate Mofetil was suspended due to side effects. Subsequently, the patient was treated with three cycles of therapeutic plasma exchange (TPE) followed, one month after the last TPE, by the anti-CD20 antibody Rituximab (RTX) (375 mg/m2weekly for 4 weeks). Eight and 16 months later the patient received other two TPE and RTX cycles, respectively. This therapeutic approach has allowed to obtain a complete skin healing persistent even after 8-month follow-up. Moreover, mitigation of Raynaud's phenomenon, resolution of alopecia, and a decline of aCL IgG/IgM and anti-Ro/SSA antibodies were observed.

1 June 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
EAEbtesam A. Abdel-Shafy
Ebtesam A. Abdel-Shafy
MKMoussa Kassim
Moussa Kassim
Alessia VignoliAlessia Vignoli
Alessia Vignoli
FMFarag Mamdouh
Farag Mamdouh
STSvitlana Tyekucheva
Svitlana Tyekucheva
Stefano CacciatoreStefano Cacciatore
Stefano Cacciatore
Spatial transcriptomics provides researchers with a powerful tool to investigate gene expression patterns within their native positional context in tissues, revealing intricate cellular relationships. However, analyzing spatial transcriptomics data presents unique challenges due to their high dimensionality and complexity. Several competitive tools have emerged, each aiming to integrate spatial dependencies into their workflow. Yet, the overall performance of these approaches remains constrained by limitations in prediction accuracy and compatibility with specific data types. Here, we introduce the third version of the KODAMA algorithm, specifically tailored for spatial transcriptomics analysis. This upgraded version incorporates a novel approach that effectively reduces data dimensionality while preserving spatial information. At its core, the KODAMA algorithm employs parallel iterations that enforce spatial constraints throughout an embedded clustering process. Our method provides the flexibility to simultaneously analyze multiple samples, streamlining analysis workflows. Additionally, it extends beyond traditional 2D analysis to accommodate multidimensional datasets, including 3D spatial information. KODAMA seamlessly integrates into various pipelines, such as Seurat and Giotto. Extensive evaluations of KODAMA on 10x Visium, Visium HD, and image-based 3D datasets demonstrate its high accuracy in spatial domain prediction. Comparative analyses against alternative dimensionality reduction techniques and spatial analysis tools consistently validate and highlight KODAMA's superior performance in unraveling the spatial organization of cellular components across both single and integrated tissue samples.